Part II: Biotech Deals — Handling of Complex Licensing Disputes

Please join Arnold & Porter for Part II of our in-person series for legal and business leaders at biotechnology companies seeking to optimize their licensing and partnering strategies.

In this CLE program, our boardroom discussion shifts from “Should you license the asset?” to “What do you do when a deal goes wrong?” Ten months after out-licensing a key asset, a fictional biotech confronts significant challenges with its partner due to several developments:

• Problems in manufacturing
• Clinical integrity and problems with the data
• IP challenges
• Milestone interpretation
• Liquidity pressures and a ticking clock
• A government inquiry

Join Arnold & Porter and your peers as you advise a Board of Directors on how to handle the complex disputes arising from their transaction.

Please note that attendance at Part 1 of this series is not necessary to participate in this disputes-focused Forum.